$JNJ Johnson & Johnson Q2 2026 Earnings

15 Jul 2026 10:20JNJ
  • Adj. EPS $2.90
  • Rev. $25.31B, est. $25.04B
  • Medicine rev. $16.38B, est. $16.12B
  • MedTech sales $8.93B, est. $8.99B, +4.5% y/y
  • Darzalex rev. $4.21B, est. $4.2B
  • Tremfya rev. $2.05B, est. $1.83B
  • Sees FY sales $100.8B to $101.4B, saw $100.3B to $101.3B
  • Sees FY adj. EPS $11.60 to $11.75, saw $11.45 to $11.65
  • Sees FY adj. oper EPS $11.50 to $11.65, saw $11.30 to $11.50
  • Qtr. div. $1.34/shr, prior $1.34 regular cash